Safety, Ethics, and the Road Ahead
Despite remarkable progress, significant challenges remain. Off-target edits — unintended cuts elsewhere in the genome — remain a concern even as newer base-editing and prime-editing technologies reduce this risk. Long-term safety data are still accumulating; the oldest CRISPR therapy patients are only a few years post-treatment.
Delivery is another hurdle. Getting editing machinery into the right cells in a living patient requires sophisticated delivery vehicles, often lipid nanoparticles or engineered viruses. Some tissues are easier to reach than others; the liver is accessible, but editing neurons in the brain remains technically demanding.
Ethical questions loom large. The scientific community maintains a moratorium on heritable germline editing following the controversial 2018 case in China where a researcher edited embryos that were carried to term. Oversight frameworks are evolving rapidly, as regulators in the US, Europe, and Asia work to create governance structures that allow beneficial applications while preventing misuse.
